KALA BIO, Inc.
KALA evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $10.4M
- Lead Asset:
- KPI-012 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for KALA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KALA
KALA BIO, Inc. is a biopharmaceutical company transitioning from ophthalmic rare-disease R&D to an on-premises AI infrastructure platform for biotech clients, following the discontinuation of its lead MSC-S product candidate.
Key risk: Cash runway critical
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$10.4M
Cash Runway
—
Lead Asset
KPI-012 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for KALA BIO, Inc..
Similar companies
KALA BIO, Inc. is a biopharmaceutical company transitioning from ophthalmic rare-disease R&D to an on-premises AI infrastructure platform for biotech clients, following the discontinuation of its lead MSC-S product candidate.
- KALA BIO is transitioning from biologics R&D to an AI platform-as-a-service model for biotech and pharma clients [sec_mda · as of 2026-08-19].
- Lead product candidate KPI-012 (MSC-S) for Persistent Corneal Epithelial Defect failed its Phase 2b CHASE trial in September 2025 and was discontinued [sec_mda · as of 2026-04-15].
- Cash & equivalents were $0.2M as of 2026-06-30 [sec]; net loss of $1.6M and shareholders' equity of $9.0M as of same date [sec].
- The company expects cash as of December 31, 2025 to fund operations into the first quarter of 2027 [sec_mda · as of 2026-04-15].
- KALA BIO is leveraging its mesenchymal stem cell secretome platform and proprietary biological datasets to develop a dedicated AI infrastructure platform [sec_mda · as of 2026-08-19].
What works
- The company has a substantial intellectual property portfolio and proprietary biological datasets from its clinical trials that it is leveraging for its new AI platform [sec_mda · as of 2026-08-19].
- KALA BIO is pivoting to a capital-light AI platform-as-a-service model, which may reduce the high R&D costs of traditional biotech [sec_mda · as of 2026-08-19].
- The company has resolved its obligations to Oxford Finance, removing a potential financial overhang [sec_mda · as of 2026-08-19].
What to weigh
- Cash & equivalents are very low at $0.2M as of 2026-06-30, indicating a critical need for additional funding [sec].
- The lead product candidate KPI-012 failed its Phase 2b trial and was discontinued, leaving the company without a clinical-stage pipeline [sec_mda · as of 2026-04-15].
- The company is in a business transition with no proven revenue from its new AI platform, and net losses continue ($1.6M net loss as of 2026-06-30) [sec].
- KALA BIO expects to continue incurring significant operating losses and is unable to predict the timing or amount of increased expenses [sec_mda · as of 2026-04-15].
From the filings
Quoted directly from source documents.
Company is transitioning to an AI platform-as-a-service model
“We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry.”
SEC MD&A · August 19, 2026
KPI-012 Phase 2b trial failed and was discontinued
“By September 2025, the CHASE trial did not meet its primary endpoints, and we determined to discontinue our development of KPI-012 and the MSC-S platform.”
SEC MD&A · April 15, 2026
Risks & what to watch (4)›
Key risks
- Cash runway critical — Cash & equivalents of $0.2M as of 2026-06-30; prior guidance of funding into Q1 2027 may be at risk [sec].
- No approved products or pipeline — Lead candidate KPI-012 discontinued; no other clinical-stage assets disclosed [sec_mda · as of 2026-04-15].
- Unproven AI business model — AI platform-as-a-service is in evaluation/transition stage with no revenue or customer commitments [sec_mda · as of 2026-08-19].
- Continued operating losses — Net loss of $1.6M in latest quarter; expects significant expenses and losses to continue [sec].
What to watch
- Progress of the AI platform-as-a-service development and any customer or partnership announcements [sec_mda · as of 2026-08-19].
- Cash position and any new financing or capital raises given the low cash balance [sec].
- Any strategic alternatives for legacy MSC-S assets or potential licensing/out-licensing [sec_mda · as of 2026-08-19].
- Regulatory or clinical updates regarding KPI-014 (MSC-S for inherited retinal diseases) if development continues [pipeline].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run KALA BIO, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KALA BIO, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.17 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 1,058,718
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KALA short interestGovernance
Frequently asked questions
What is the AI investment thesis for KALA BIO, Inc.?
KALA BIO, Inc. is a biopharmaceutical company transitioning from ophthalmic rare-disease R&D to an on-premises AI infrastructure platform for biotech clients, following the discontinuation of its lead MSC-S product candidate.
What is KALA BIO, Inc.'s lead drug candidate?
KALA BIO, Inc.'s most advanced tracked candidate is KPI-012 (Phase 2) for Persistent Corneal Epithelial Defect.
Who is the CEO of KALA BIO, Inc.?
Mr. Avi Minkowitz is the chief executive officer of KALA BIO, Inc. (KALA).
Where is KALA BIO, Inc. headquartered?
KALA BIO, Inc. (KALA) is headquartered in Arlington, MA, United States.
What therapeutic areas does KALA BIO, Inc. focus on?
KALA BIO, Inc. develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.